PMID- 21868497
OWN - NLM
STAT- MEDLINE
DCOM- 20111121
LR  - 20220311
IS  - 1533-3450 (Electronic)
IS  - 1046-6673 (Print)
IS  - 1046-6673 (Linking)
VI  - 22
IP  - 10
DP  - 2011 Oct
TI  - Asymptomatic autoantibodies associate with future anti-glomerular basement 
      membrane disease.
PG  - 1946-52
LID - 10.1681/ASN.2010090928 [doi]
AB  - The pathophysiology of anti-glomerular basement membrane (anti-GBM) disease 
      before clinical presentation is unknown. The presence of anti-GBM, 
      anti-proteinase 3 (PR3), and anti-myeloperoxidase (MPO) antibodies associate with 
      the disease at the time of diagnosis, but little is known about the presence of 
      these autoantibodies before diagnosis. We used serum samples from the Department 
      of Defense Serum Repository to conduct a case-control study involving 30 patients 
      diagnosed with anti-GBM disease and 30 healthy controls matched for the age, 
      gender, race, and age of the serum samples. We analyzed a maximum of three 
      samples from each subject: the most recent sample before diagnosis, the 
      penultimate sample before diagnosis, and the oldest sample available; the average 
      time between the most recent sample and diagnosis was 195 days (range, 4 to 1346 
      days). Elevated anti-GBM levels (>/=3 U/ml) were present in four patients, all less 
      than 1 year before diagnosis but in no controls. Detectable anti-GBM antibody 
      levels (>/=1 U/ml but <3 U/ml) in a single serum sample before diagnosis were more 
      frequent in cases than controls (70% versus 17%, P < 0.001). Only study patients 
      had detectable anti-GBM levels in multiple samples before diagnosis (50% versus 
      0%, P < 0.001). Almost all patients had detectable anti-PR3 and/or anti-MPO that 
      preceded the onset of disease. Among patients with a clear antecedent antibody, 
      anti-PR3 or anti-MPO always became detectable before the anti-GBM antibody. In 
      summary, our data describe the subclinical formation of autoantibodies, which 
      improves our understanding of the pathophysiology of anti-GBM disease.
FAU - Olson, Stephen W
AU  - Olson SW
AD  - Department of Nephrology, Walter Reed Army Medical Center, Washington, DC 20307, 
      USA. Stephen.w.olson@us.army.mil
FAU - Arbogast, Charles B
AU  - Arbogast CB
FAU - Baker, Thomas P
AU  - Baker TP
FAU - Owshalimpur, David
AU  - Owshalimpur D
FAU - Oliver, David K
AU  - Oliver DK
FAU - Abbott, Kevin C
AU  - Abbott KC
FAU - Yuan, Christina M
AU  - Yuan CM
LA  - eng
PT  - Journal Article
DEP - 20110825
PL  - United States
TA  - J Am Soc Nephrol
JT  - Journal of the American Society of Nephrology : JASN
JID - 9013836
RN  - 0 (Autoantibodies)
RN  - 0 (antiglomerular basement membrane antibody)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.4.21.76 (Myeloblastin)
SB  - IM
EIN - J Am Soc Nephrol. 2011 Dec;22(12):2332
CIN - J Am Soc Nephrol. 2011 Oct;22(10):1783-4. PMID: 21903994
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Anti-Glomerular Basement Membrane Disease/*immunology
MH  - Autoantibodies/*blood
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myeloblastin/*immunology
MH  - Peroxidase/*immunology
MH  - Sex Factors
MH  - Time Factors
MH  - Young Adult
PMC - PMC3279953
EDAT- 2011/08/27 06:00
MHDA- 2011/12/13 00:00
PMCR- 2012/10/01
CRDT- 2011/08/27 06:00
PHST- 2011/08/27 06:00 [entrez]
PHST- 2011/08/27 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
PHST- 2012/10/01 00:00 [pmc-release]
AID - ASN.2010090928 [pii]
AID - 2010090928 [pii]
AID - 10.1681/ASN.2010090928 [doi]
PST - ppublish
SO  - J Am Soc Nephrol. 2011 Oct;22(10):1946-52. doi: 10.1681/ASN.2010090928. Epub 2011 
      Aug 25.